Baldino brings nearly three decades of healthcare leadership experience to EGS as it works to advance the field of advanced endoluminal procedural techniques
SAN MATEO, Calif. (May 1, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced today that industry veteran Skip Baldino has been named President and CEO. Mr. Baldino brings nearly three decades of healthcare experience to EGS, including four years as President, Americas for Given Imaging Ltd., a leader in gastrointestinal diagnostics and imaging that Covidien acquired for $860 million in March 2014.
“I’m thrilled to join EGS at this pivotal point in the company’s evolution,” Mr. Baldino said. “It’s clear that patients suffering from GERD need an option beyond palliative medication to mask the symptoms of the condition or invasive surgery to overcorrect the underlying cause. Based on the growing body of clinical evidence, I believe that the TIF® procedure has the potential to bridge that gap, providing a viable, much-needed treatment option for millions of GERD sufferers. I am excited to work with the team at EGS, and collaborate with the company’s customers and their respective societies to utilize the clinical evidence on TIF to further develop the market for endoscopic treatment of GERD.”
Prior to his four years at Given Imaging, Mr. Baldino served as a divisional Vice President for Abbott Laboratories for eight years, during which he held key commercial leadership roles in several Abbott divisions – diabetes care, diagnostics, medical products (corporate), hospital products (now known as Hospira), health systems and specialty products. His experience encompasses various key customer segments, as well as a wide range of product portfolios, product lifecycles, new product launches and integrations. Mr. Baldino graduated with a bachelor’s degree in Marketing from Philadelphia University.
“Skip is an ideal leader to help guide EGS in its mission to advance the field of endoluminal procedural techniques, and introduce an entirely new treatment paradigm for patients,” said Michael Kleine, Chairman of the Board, EndoGastric Solutions. “Through his experience at Given Imaging, he has a deep understanding of digestive diseases and the endoscopy market in the U.S. During his distinguished 26-year career at Abbott Laboratories, Mr. Baldino established an outstanding track record of consistent and high performing financial and organizational success.”
EGS recently released data showing that the TIF procedure can eliminate troublesome regurgitation and inflammation. The company will present additional data at the upcoming Digestive Disease Week®, which runs from May 3 to 6 in Chicago.
“As EGS continues to generate high quality clinical evidence on the TIF procedure, and innovate the EsophyX platform we’re excited to have Skip on board,” said Michael Carusi, EGS board member and General Partner of Advanced Technology Ventures. “The breadth and depth of his commercial experience, as well as his key relationships with surgeons and gastroenterologists, will be vital as the company continues to grow and expand the market for endoluminal procedures to treat GERD.”